Meeting
2023 ASCO Annual Meeting
High dose alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Results from the randomized phase 3 OLIGO study.
Authors
Annemiek Van Ommen-Nijhof
The Netherlands Cancer Institute, Amsterdam, Netherlands
Annemiek Van Ommen-Nijhof , Tessa Gerjanne Steenbruggen , Terry G. Wiersma , Sara Balduzzi , Antonios Daletzakis , Marjo Holtkamp , Marjolein Delfos , Karin Beelen , Ester Siemerink , Joan B. Heijns , Ingrid A. Mandjes , Jelle Wesseling , Efraim H. Rosenberg , Marie-Jeanne T.F.D Vrancken Peeters , Sabine C. Linn , Gabe S. Sonke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT01646034
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1097)
DOI
10.1200/JCO.2023.41.16_suppl.1097
Abstract #
1097
Poster Bd #
318
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3).
First Author: Sreenivasa R Chandana
Poster
2021 ASCO Annual Meeting
A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).
First Author: Marc Thomas Roth
Poster
2021 ASCO Annual Meeting
Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.
First Author: Matteo Lambertini
Poster
2020 ASCO Virtual Scientific Program
A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
First Author: Peter Schmid